{"prompt": "['CONFIDENTIAL', 'Protocol ANB019-002 - Amendment 5', 'Appendix 3', 'Clinical Laboratory Tests', 'The tests detailed in Table 5 will be performed by the central laboratory. The time points are', 'specified in Schedule of Activities (see Section 1.3).', 'Local laboratory tests will be allowed in the event that the central laboratory results will not', 'be available immediately and the Investigator need to take an immediate decision for any', 'safety concerns. If a local sample is required, it is important that the sample for central', 'analysis is obtained at the same time.', 'Urine pregnancy dipstick will be performed at the study center prior to study treatment', 'administration.', 'Protocol-specific requirements for inclusion or exclusion of subjects are detailed in', 'Section 5.0 of the protocol.', 'Additional tests may be performed at any time during the study as determined necessary by', 'the Investigator or required by local regulations.', 'Table 5', 'Protocol-required Safety Laboratory Assessments', 'Laboratory', 'Parameters', 'Assessments', 'Hematology', 'Hemoglobin', 'Red Blood Cell Count', 'Hematocrit', 'White Blood Cell Count (WBC) with', 'Differential:', 'Neutrophils', 'Mean cell hemoglobin (MCH)', 'Lymphocytes', 'Mean cell volume (MCV)', 'Monocytes', 'Mean cell hemoglobin', 'Eosinophils', 'concentration (MCHC)', 'Platelet count', 'Basophils', 'Clinical', 'Alanine Aminotransferase (ALT)', 'Creatinine', 'Chemistry', 'Albumin', 'Gamma glutamyl transferase (GGT)', 'Alkaline phosphatase (ALP)', 'Glucose', 'Aspartate Aminotransferase (AST)', 'Potassium', 'Bicarbonate', 'Phosphate (Inorganic)', 'Bilirubin (Total)', 'Protein (Total)', 'Bilirubin (Direct-only if total is', 'Sodium', 'elevated)', 'Calcium', 'Blood urea nitrogen (urea)', 'Chloride', 'Creatine Kinase (CK)', 'Uric acid', 'Triglycerides', 'Lactate dehydrogenase', 'human C-reactive protein (hCRP)', '29 October 2019', '67']['CONFIDENTIAL', 'Protocol ANB019-002 - Amendment 5', 'Laboratory', 'Parameters', 'Assessments', 'Troponin', 'Total Cholesterol', 'Serum pregnancy', 'Human chorionic gonadotropin (hCG) pregnancy test (as needed for women', 'of childbearing potential)', 'FSH', 'As needed in women of non-childbearing potential only (Postmenopausal', 'woman aged over 45 years with at least 1 year of amenorrhea)', 'Urinalysis', 'Bilirubin', 'pH', 'Blood', 'Protein', 'Glucose', 'Specific gravity', 'Ketones', 'Urobilinogen', 'Leukocytes', 'Microbiology (At discretion of', 'Investigator based on urinalysis', 'results)', 'Nitrites', 'Microscopy (At discretion of', 'Investigator based on urinalysis', 'results)', 'Viral serology', 'Hepatitis B surface antigen', 'Hepatitis C Antibody', 'Human immunodeficiency virus', 'Antibodies', 'Tuberculosis', 'Quantiferon\u00ae - TB Gold In-tube, the third-generation test (If the test', '(TB) screening', 'indeterminate it can be retested only once)', 'NOTES: Please see Schedule of Activities (Section 1.3) for laboratory tests time points.', 'PK and ADA samples will be collected as detailed in the Schedule of Activities All blood samples', 'must be drawn prior to administration of the study drug on Day 1. The date and exact time of', 'sample collection must be recorded', 'Investigators must document their review of each laboratory safety report.', '29 October 2019', '68']['CONFIDENTIAL', 'Protocol ANB019-002 - Amendment 5', 'Appendix 4', 'Adverse Events: Definitions and Procedures for Recording,', 'Evaluating, Follow-up, and Reporting', 'Definition of AE', 'AE Definition', 'An AE is any untoward medical occurrence in a subject or subject, temporally associated with the use', 'of study treatment, whether or not considered related to the study treatment.', 'NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal', 'laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of', 'study treatment.', 'Events Meeting the AE Definition', 'Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or other safety', 'assessments (eg, ECG, radiological scans, vital signs measurements), including those that worsen from', 'baseline, considered clinically significant in the medical and scientific judgment of the Investigator (ie,', 'not related to progression of underlying disease).', 'Exacerbation of a chronic or intermittent pre-existing condition including either an increase in', 'frequency and/or intensity of the condition.', 'New conditions detected or diagnosed after study treatment administration even though it may have', 'been present before the start of the study.', 'Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction.', 'Signs, symptoms, or the clinical sequelae of a suspected overdose of either study treatment or a', 'concomitant medication. Overdose per se will not be reported as an AE/SAE unless it is an intentional', 'overdose taken with possible suicidal/self-harming intent. Such overdoses should be reported', 'regardless of sequelae.', '\"Lack of efficacy\" or \"failure of expected pharmacological action\" per se will not be reported as an AE', 'or SAE. Such instances will be captured in the efficacy assessments. However, the signs, symptoms,', 'and/or clinical sequelae resulting from lack of efficacy will be reported as AE or SAE if they fulfil the', 'definition of an AE or SAE.', 'Events NOT Meeting the AE Definition', 'Any clinically significant abnormal laboratory findings or other abnormal safety assessments which are', 'associated with the underlying disease, unless judged by the Investigator to be more severe than', \"expected for the subject's condition.\", 'The disease/disorder being studied or expected progression, signs, or symptoms of the disease/disorder', \"being studied, unless more severe than expected for the subject's condition.\", 'Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that leads to the', 'procedure is the AE.', 'Situations in which an untoward medical occurrence did not occur (social and/or convenience', 'admission to a hospital).', 'Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present or detected at the', 'start of the study that do not worsen.', '29 October 2019', '69']\n\n###\n\n", "completion": "END"}